{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:21:42Z","timestamp":1781796102626,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,20]]},"DOI":"10.7759\/cureus.82631","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T16:17:36Z","timestamp":1745165856000},"source":"Crossref","is-referenced-by-count":1,"title":["Nilotinib Versus Imatinib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)"],"prefix":"10.7759","author":[{"given":"Fabeha","family":"Zafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Poombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laraib","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diptish","family":"Wankhade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Winayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Mustafa","family":"Ali Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti Sagar","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasan","family":"G.C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truc","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneeth","family":"Mylavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review","volume":"12","author":"Sampaio MM","year":"2021","unstructured":"Sampaio MM, Santos ML, Marques HS, et al.. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review. World J Clin Oncol. 2021, 12:69-94. 10.5306\/wjco.v12.i2.69","journal-title":"World J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/187125","article-title":"Complex variant t(9;22) chromosome translocations in five cases of chronic myeloid leukemia","volume":"2009","author":"Valencia A","year":"2009","unstructured":"Valencia A, Cervera J, Such E, et al.. Complex variant t(9;22) chromosome translocations in five cases of chronic myeloid leukemia. Adv Hematol. 2009, 2009:187125. 10.1155\/2009\/187125","journal-title":"Adv Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s3993","article-title":"Targeted treatment of chronic myeloid leukemia: role of imatinib","volume":"2","author":"Tamascar I","year":"2009","unstructured":"Tamascar I, Ramanarayanan J. Targeted treatment of chronic myeloid leukemia: role of imatinib. Onco Targets Ther. 2009, 2:63-71. 10.2147\/ott.s3993","journal-title":"Onco Targets Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.003","article-title":"Second-generation tyrosine kinase inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs","volume":"6","author":"Breccia M","year":"2014","unstructured":"Breccia M, Alimena G. Second-generation tyrosine kinase inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs. Mediterr J Hematol Infect Dis. 2014, 6:e2014003. 10.4084\/MJHID.2014.003","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang J","year":"2015","unstructured":"Wang J, Shen ZX, Saglio G, et al.. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015, 125:2771-8. 10.1182\/blood-2014-09-601674","journal-title":"Blood"},{"key":"ref9","unstructured":"Nilotinib vs imatinib in adult patients with Philadelphia (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) (ENEST). (2011). Accessed. March 21, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00519090."},{"key":"ref10","unstructured":"A study of imatinib versus nilotinib in adult patients with newly diagnosed philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) (ENESTnd). (2020). Accessed. March 21, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00471497."},{"key":"ref11","unstructured":"Nilotinib versus standard imatinib (400\/\u200b600 mg every day (QD)) comparing the kinetics of complete molecular response for chronic myelogenous leukemia in chronic phase (CML-CP) Pts with evidence of persistent leukemia by real-time quantitative polymerase chain reaction (RQ-PCR). (2016). Accessed. March 21, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00760877."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener C","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G, Sant M. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020, 4:2723-35. 10.1182\/bloodadvances.2019001329","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"Mealing S","year":"2013","unstructured":"Mealing S, Barcena L, Hawkins N, Clark J, Eaton V, Hirji I, Davis C. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp Hematol Oncol. 2013, 2:5. 10.1186\/2162-3619-2-5","journal-title":"Exp Hematol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6039-9","article-title":"Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis","volume":"19","author":"Tang L","year":"2019","unstructured":"Tang L, Zhang H, Peng YZ, et al.. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. BMC Cancer. 2019, 19:849. 10.1186\/s12885-019-6039-9","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.09.004","article-title":"Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis","volume":"40","author":"Signorovitch J","year":"2014","unstructured":"Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev. 2014, 40:285-92. 10.1016\/j.ctrv.2013.09.004","journal-title":"Cancer Treat Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1008","article-title":"Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis","volume":"19","author":"Li S","year":"2023","unstructured":"Li S, Wang T, Zhong Y, Dai S. Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis. Future Oncol. 2023, 19:1215-27. 10.2217\/fon-2022-1008","journal-title":"Future Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12052","article-title":"Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization","volume":"90","author":"Drucker AM","year":"2013","unstructured":"Drucker AM, Wu S, Busam KJ, Berman E, Amitay-Laish I, Lacouture ME. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol. 2013, 90:142-50. 10.1111\/ejh.12052","journal-title":"Eur J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.15226\/ijhbd\/3\/1\/00120","article-title":"Cutaneous manifestations of nilotinib","volume":"3","author":"Yassin MA","year":"2018","unstructured":"Yassin MA, Mudawi D, Nashwan A, Kassem N. Cutaneous manifestations of nilotinib. Int J Blood Res Disord. 2018, 3:1-3. 10.15226\/ijhbd\/3\/1\/00120","journal-title":"Int J Blood Res Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer JB","year":"2007","unstructured":"Singer JB, Shou Y, Giles F, et al.. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007, 21:2311-5. 10.1038\/sj.leu.2404827","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.5538.5538","article-title":"Polymorphism of UGT1A1 and frequency of hyperbilirubinemia in patients with chronic myeloid leukemia treated by nilotinib","volume":"124","author":"Bykova A","year":"2014","unstructured":"Bykova A, Abdullaev A, Gusarova G, et al.. Polymorphism of UGT1A1 and frequency of hyperbilirubinemia in patients with chronic myeloid leukemia treated by nilotinib. Blood. 2014, 124:5538. 10.1182\/blood.V124.21.5538.5538","journal-title":"Blood"},{"key":"ref22","unstructured":"Cancer Stat Facts. leukemia \u2014 chronic lymphocytic leukemia (CLL). (2018). Accessed: March 21, 2024: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.966182","article-title":"Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis","volume":"9","author":"Li S","year":"2022","unstructured":"Li S, He J, Zhang X, Cai Y, Liu J, Nie X, Shi L. Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis. Front Cardiovasc Med. 2022, 9:966182. 10.3389\/fcvm.2022.966182","journal-title":"Front Cardiovasc Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023, 8:262. 10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341821-nilotinib-versus-imatinib-in-philadelphia-chromosome-positive-chronic-myeloid-leukemia-ph-cml-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-rcts","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T16:17:37Z","timestamp":1745165857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341821-nilotinib-versus-imatinib-in-philadelphia-chromosome-positive-chronic-myeloid-leukemia-ph-cml-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-rcts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.82631","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,20]]}}}